Latest Articles
Merck's ADC candidate meets goals in endometrial cancer study - MSN
Merck's ADC candidate meets goals in endometrial cancer study MSN
Published: May 31, 2026, 5:59 a.m.
Puxitatug Samrotecan Elicits High Response Rate in Select Endometrial Cancers - OncLive
Puxitatug Samrotecan Elicits High Response Rate in Select Endometrial Cancers OncLive
Published: May 30, 2026, 9:59 p.m.
Endometrial Cancer Survivors Face Harder Path to IVF Success - MedPage Today
Endometrial Cancer Survivors Face Harder Path to IVF Success MedPage Today
Published: May 30, 2026, 4:38 p.m.
Dostarlimab Plus Chemo May Offer Cure to Some Advanced Endometrial Cancer Patients - Cancer Therapy Advisor
Dostarlimab Plus Chemo May Offer Cure to Some Advanced Endometrial Cancer Patients Cancer Therapy Advisor
Published: May 30, 2026, 4 a.m.
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients - News-Medical
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients News-Medical
Published: May 30, 2026, 2:16 a.m.
Long-Term RUBY Data Show Potential for Curative Intent With Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer - OncLive
Long-Term RUBY Data Show Potential for Curative Intent With Dostarlimab Combo Shows Durable Disease Control in dMMR/MSI-H Endometrial Cancer OncLive
Published: May 30, 2026, 12:24 a.m.
Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer - OncLive
Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer OncLive
Published: May 29, 2026, 11:57 p.m.
Dostarlimab Plus Chemotherapy Yields Curative Potential in dMMR/MSI-H Endometrial Cancer - CancerNetwork
Dostarlimab Plus Chemotherapy Yields Curative Potential in dMMR/MSI-H Endometrial Cancer CancerNetwork
Published: May 29, 2026, 10:40 p.m.
Dostarlimab/Chemo Shows Curative Potential in dMMR/MSI-H Advanced Endometrial Cancer - Targeted Oncology
Dostarlimab/Chemo Shows Curative Potential in dMMR/MSI-H Advanced Endometrial Cancer Targeted Oncology
Published: May 29, 2026, 10:11 p.m.
Optimizing Biomarker-Driven Treatment and Immune Checkpoint Inhibitor Counseling in Endometrial Cancer - Pharmacy Times
Optimizing Biomarker-Driven Treatment and Immune Checkpoint Inhibitor Counseling in Endometrial Cancer Pharmacy Times
Published: May 28, 2026, 8:50 p.m.
Link copied to clipboard!